Company name: Ube Industries, Ltd.
Representative: Hiroaki Tamura
President and Representative Director
Shares listed on: First Section of Tokyo Stock Exchange,
Fukuoka Stock Exchange
Security code number: 4208
Contact: Yasuko Sakamoto
General Manager, IR/PR Department
Tel: +81-3-5419-6110

FDA Advisory Committee Issues Approval Recommendation for Prasugrel, Antiplatelet Agent

TOKYO, February 4, 2009 — Ube Industries, Ltd. today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee has issued an approval recommendation for prasugrel. Prasugrel is an investigational oral antiplatelet agent discovered by Ube Industries and Daiichi Sankyo Co., Ltd., and co-developed in the global market by Daiichi Sankyo and Eli Lilly and Company.

The Advisory Committee voted that prasugrel should be approved since it has been shown to be effective and acceptably safe for the treatment of patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI). This announcement by Ube Industries follows a separate joint press release issued by Daiichi Sankyo and Eli Lilly.

The FDA will now continue to review the new drug application for prasugrel. The FDA is not bound by the committee's recommendation, but it takes its advice into consideration when reviewing new drug applications.

Prasugrel is an antiplatelet agent that works by inhibiting platelet activation and subsequent aggregation. By preventing platelets from clumping or sticking together, which can result in clogged arteries, antiplatelet agents may help reduce cardiovascular events such as heart attacks. If approved, prasgurel will be a treatment for patients with acute coronary syndromes who are undergoing PCI. Lilly, on behalf of its alliance partner, Daiichi Sankyo, submitted a New Drug Application for prasugrel to the U.S. Food and Drug Agency (FDA) in December 2007, and a Marketing Authorization Application to the European Medicines Agency (EMEA) in February 2008. In December 2008, the Committee for Medical Products for Human Use (CHMP) of EMEA issued a positive opinion recommending approval of prasugrel .

Ube Industries earlier this year unveiled its Stage Up 2009 mid-term management plan, which identifies the Company's pharmaceuticals business as a developing business with future potential for growth and profitability. Accordingly, Ube Industries is engaging in pharmaceuticals R&D with the goal of discovering new and proprietary pharmaceutical agents that will benefit society. Ube Industries co-developed the Talion® antiallergic agent with Tanabe Seiyaku Co., Ltd. (presently Mitsubishi Tanabe Pharma Corporation), and co-developed the Calblock® antihypertensive agent

with Sankyo Co., Ltd. (presently Daiichi Sankyo). Talion® and Calblock® were approved and marketed in Japan in 2000 and 2003 respectively, and it is anticipated that they will be followed by early approval of prasugrel in U.S. and Europe.

- Talion® is a registered trademark of Mitsubishi Tanabe Pharma Corporation.
- Calblock® is a registered trademark of Daiichi Sankyo Co., Ltd.